Taurine Protects from Pentylenetetrazole-Induced Behavioral and Neurochemical Changes in Zebrafish

被引:0
作者
Barbara D. Fontana
Paola R. Ziani
Julia Canzian
Nathana J. Mezzomo
Talise E. Müller
Matheus M. dos Santos
Vania L. Loro
Nilda V. Barbosa
Carlos F. Mello
Denis B. Rosemberg
机构
[1] Federal University of Santa Maria,Laboratory of Experimental Neuropsychobiology, Department of Biochemistry and Molecular Biology, Natural and Exact Sciences Center
[2] Federal University of Santa Maria,Graduate Program in Biological Sciences: Toxicological Biochemistry
[3] Federal University of Santa Maria,Graduate Program in Pharmacology
[4] The International Zebrafish Neuroscience Research Consortium (ZNRC),undefined
来源
Molecular Neurobiology | 2019年 / 56卷
关键词
Epilepsy; Seizure-like behaviors; Neuroprotection; Pentylenetetrazole; Oxidative stress; Zebrafish;
D O I
暂无
中图分类号
学科分类号
摘要
Epilepsy is a common neurological disorder characterized by recurrent unprovoked seizures, which culminate in various neurobehavioral and neurochemical changes. Taurine (TAU) is an amino sulfonic acid which acts an endogenous inhibitory neuromodulator. Moreover, TAU displays intrinsic antioxidant activity, contributing to its beneficial actions in the CNS. Here, we evaluated whether TAU pretreatment protects from pentylenetetrazole (PTZ)-induced behavioral alterations and oxidative stress-related parameters in zebrafish brain tissue. Fish were pretreated with 42, 150, and 400 mg/L TAU (40 min) and further exposed to 10 mM PTZ (20 min) to analyze the seizure-like behaviors. As a positive control, another group was previously treated with 75 μM diazepam (DZP). Afterwards, biochemical experiments were performed. All TAU concentrations tested decreased seizure intensity in the first 150 s. Importantly, 150 mg/L TAU attenuated seizure-like behavioral scores, decreased seizure intensity, reduced the frequency of clonic-like seizures (score 4), and increased the latency to score 4. TAU (150 mg/L) also prevented oxidative stress in PTZ-challenged fish by decreasing lipid peroxidation and protein carbonylation and preventing changes on nonprotein thiol levels. No significant changes were observed in MTT assay and LDH activity. Differently than observed in DZP group, TAU did not affect the overall swimming activity of fish, suggesting different mechanisms of action. Collectively, we show that TAU attenuates PTZ-induced seizure-like behaviors and brain oxidative stress in zebrafish, suggesting the involvement of antioxidant mechanisms in neuroprotection.
引用
收藏
页码:583 / 594
页数:11
相关论文
共 464 条
[1]  
Fisher RS(2005)Photic- and pattern-induced seizures: a review for the Epilepsy Foundation of America Working Group Epilepsia 46 1426-1441
[2]  
Harding G(2013)Seizures induced by pentylenetetrazole in the adult zebrafish: a detailed behavioral characterization PLoS One 8 e54515-2202
[3]  
Erba G(2013)Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs PLoS One 8 e54166-504
[4]  
Barkley GL(2006)Comparison of seizure phenotype and neurodegeneration induced by systemic kainic acid in inbred, outbred, and hybrid mouse strains Eur J Neurosci 24 2191-28
[5]  
Wilkins A(2009)Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms Nat Rev Neurol 5 492-64
[6]  
Mussulini BH(2011)Recording the adult zebrafish cerebral field potential during pentylenetetrazole seizures J Neurosci Methods 200 20-368
[7]  
Leite CE(2011)The role of the ketogenic diet on oxidative stress present in experimental epilepsy J Epilepsy Clin Neurophysiol 17 54-768
[8]  
Zenki KC(2011)Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs Seizure 20 359-104
[9]  
Moro L(2005)Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression Neuroscience 131 759-1255
[10]  
Baggio S(2016)Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures Epilepsy Behav 57 95-S17